ZofranLegal Announces GSK Reached $3 Billion Settlement In Zofran Case

April 20, 2015 – – GSK is one of the world’s leading pharmaceutical companies and has an average annual revenue of some $39 billion. In 2012, a number of civil and criminal charges were filed against the company by the US Department Of Justice. According to the government, GSK had “unlawfully promoted” a number of drugs and “failed to report” safety data to the FDA. They have now reached a $3 billion settlement, which is the largest settlement of its kind to date in the US. However, it should be noted that none of these DOJ lawsuits had to do with birth defects, unlike the lawsuits being handled by the attorneys sponsoring ZofranLegal.com.

“Our members are among the first to file lawsuits against GSK alleging that Zofran was the cause of cleft palate, atrial septal defect, ventricular septal defect, kidney malformations, and many other child birth defects,” says Michael Monheit. “We are continuing to investigate the current science that exists to ascertain whether there are links to other defects like cranioskeletal defects.”

The DOJ’s case involved several drugs being manufactured by GSK. And according to the DOJ press release regarding the settlement, the company agreed to plead guilty on three of the criminal counts.

“GlaxoSmithKline pled guilty on some criminal counts,” stated a representative of the Department of Justice (DOJ). “This included introducing Wellbutrin and Paxil in interstate commerce, as well as failing to report to the FDA the safety data about Avandia.”

As a result, GSK has agreed to pay more than $1 billion in settlement although court documents indicate that the settlement “is neither an admission of facts or liability by GSK.” The DOJ alleged in its charges that GSK “knowingly promoted the sale and use of Zofran for a variety of conditions other than those for which its use was approved as safe and effective by the FDA.” The settlement specifically referenced the promotion to women suffering from hyperemesis or pregnancy related nausea. GSK continues to deny the DOJs allegations that it made unsubstantiated and/or false representations about the safety of Zofran regarding the aforementioned use. It was further alleged that GSK offered paid illegal remuneration to induce healthcare providers to prescribe Zofran for treating hyperemesis and pregnancy related nausea.

It should be noted, however, that the money in the settlement with the DOJ is not a settlement that relates to the current lawsuits being filed against GSK alleging child birth defects caused by Zofran. Meanwhile, as can be seen at www.zofranlegal.com, there have been several studies and developing science that associate a link between Zofran and child birth defects. This includes congenital heart defects and cleft palate.

Various lawsuits are pending against GSK at the moment regarding congenital birth defects allegedly caused by Zofran when it was prescribed to pregnant women for severe morning sickness. No settlement has been reached in these cases yet. Additionally, since each case is individual, it is not clear yet how these cases will fare in court and how much compensation would be received if any. Please click here for more information about the Zofran litigation.

CONTACT DETAILS:
ZofranLegal.com
Michael Monheit – 1-877-620-8411
1368 Barrowdale Road
Rydal, PA 19046

ReleaseID: 60000598